(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/212803 A2

(51) International Patent Classification:
A61K 40/11 (2025.01) *A61K 40/31* (2025.01)

(21) International Application Number:
PCT/US2025/022794

(22) International Filing Date:
02 April 2025 (02.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/574,150	03 April 2024 (03.04.2024)	US
63/696,081	18 September 2024 (18.09.2024)	US
63/717,157	06 November 2024 (06.11.2024)	US

(71) Applicants: **UMOJA BIOPHARMA, INC.** [US/US]; 1150 Eastlake Avenue E., Suite 400, Seattle, Massachusetts 98109 (US). **IASO BIOTHERAPEUTICS USA LIMITED** [US/US]; Lab# 209, 5941 Optical Ct, San Jose, California 95138 (US).

(72) Inventors: **NICOLAI, Christopher**; c/o Umoja Biopharma, Inc., 1150 Eastlake Avenue E., Suite 400, Seattle, Washington 98109 (US). **QIN, Jim**; c/o Umoja Biopharma, Inc., 1150 Eastlake Avenue E., Suite 400, Seattle, Washington 98109 (US).

(74) Agent: **HECKER, Peter** et al.; One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/212803 A2

(54) Title: LENTIVIRAL DELIVERY OF ANTI-CD22 CHIMERIC ANTIGEN RECEPTORS

(57) Abstract: Provided herein are particles comprising polynucleotide constructs for generating cells expressing anti-CD22 chimeric antigen receptor, as well as vectors, such as lentiviral vectors, comprising same, cells comprising same, and methods of using same. Some embodiments include a surface-engineered lentiviral vector. In some embodiments, the lentiviral vector further encodes a synthetic receptor protein.